Wedbush Reiterates Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA)

Wedbush reiterated their outperform rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note released on Tuesday,RTT News reports. The brokerage currently has a $40.00 target price on the stock. Wedbush also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($2.46) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($2.94) EPS.

Several other equities research analysts also recently weighed in on ORKA. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Lifesci Capital began coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective for the company. Stifel Nicolaus began coverage on Oruka Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Thursday, October 31st. Finally, TD Cowen initiated coverage on Oruka Therapeutics in a report on Monday, September 16th. They set a “buy” rating for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Price Performance

ORKA stock opened at $20.75 on Tuesday. The firm has a market capitalization of $726.23 million, a P/E ratio of -3.31 and a beta of 0.87. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88. The company has a 50 day moving average price of $26.25.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. FMR LLC acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $114,763,000. RTW Investments LP purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $45,359,000. Braidwell LP acquired a new position in Oruka Therapeutics during the 3rd quarter worth approximately $12,640,000. Great Point Partners LLC acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $12,614,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $11,822,000. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.